Clinical trial
Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)
NCT00093158 · The Medicines Company, Industry · Completed
Key facts
| NCT number | NCT00093158 |
|---|---|
| Title | Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS) |
| Official title | The ACUITY Trial: A Randomized Comparison of Angiomax (Bivalirudin) Versus Heparin (Unfractionated Heparin or Enoxaparin) in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-Segment Elevation |
| Lead sponsor | The Medicines Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Unstable Angina, Myocardial Infarction, Acute Disease |
| Intervention type | Drug |
| Interventions | Angiomax (bivalirudin) anticoagulant |
| Enrollment | 13,800 |
| Start date | Aug 1, 2003 |
| Completion | Jan 1, 2007 |
| First posted | Oct 7, 2004 |
| Last update posted | Aug 21, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: